Citi analyst Yigal Nochomovitz raised the firm’s price target on Arvinas (ARVN) to $18 from $15 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Regulatory Turbulence: How FDA Disruptions and Budget Cuts Threaten Arvinas Holding Company’s Drug Development Timelines
- Arvinas price target raised to $11 from $9 at Wedbush
- Arvinas price target raised to $19 from $14 at Evercore ISI
- Arvinas price target raised to $20 from $16 at Piper Sandler
- Arvinas: Strong Pipeline Momentum, De-Risked Cash Runway, and Attractive Risk‑Reward Support Buy Rating